ArticleAME case reports2026
A successful treatment of urticaria pigmentosa with omalizumab in a pediatric patient: a case report.
Article in AME case reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Cutaneous mastocytosis (CM) is a rare disorder characterized by abnormal mast cell proliferation limited to the skin. Conventional treatments including antihistamines and corticosteroids often provide suboptimal symptom control, with less than 50% of patients responding adequately to H1-antihistamine therapy. Omalizumab, a humanized monoclonal antibody that inhibits immunoglobulin E (IgE) binding to mast cells, represents a promising therapeutic alternative for refractory cases. Case Description: We report a 14-year-old Middle Eastern female with a 1-year history of intensely pruritic, hyperpigmented macules significantly impacting her quality of life. Physical examination revealed widespread excoriated erythematous and brown macules with positive Darier's sign. Histopathological examination showed CD117-positive mast cells, confirming CM diagnosis. Laboratory investigations were normal except for mildly elevated IgE (217 IU/mL). Conventional management with antihistamines, corticosteroids, and Montelukast provided minimal improvement, with persistent urticarial attacks requiring systemic steroid pulses. Omalizumab was initiated at 150 mg monthly subcutaneously and increased to 300 mg monthly due to relapses. Following dose optimization, the patient achieved complete symptom resolution and improved quality of life without adverse events. Conclusions: This represents the first documented pediatric CM case in Saudi Arabia successfully treated with omalizumab. The treatment demonstrated remarkable efficacy when conventional therapies failed, with excellent safety profile. Omalizumab may serve as a viable therapeutic alternative for pediatric patients with refractory CM. Further clinical trials are needed to establish optimal treatment protocols.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.